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Myopia has been predicted to affect approximately 50% of the world’s population based
on trending myopia prevalence figures. Critical to minimizing the associated adverse
visual consequences of complicating ocular pathologies are interventions to prevent or
delay the onset of myopia, slow its progression, and to address the problem of mechanical
instability of highly myopic eyes. Although treatment approaches are growing in number,
evidence of treatment efficacy is variable. This article reviews research behind such
interventions under four categories: optical, pharmacological, environmental (behavioral),
and surgical. In summarizing the evidence of efficacy, results from randomized controlled
trials have been given most weight, although such data are very limited for some
treatments. The overall conclusion of this review is that there are multiple avenues for
intervention worthy of exploration in all categories, although in the case of optical,
pharmacological, and behavioral interventions for preventing or slowing progression of
myopia, treatment efficacy at an individual level appears quite variable, with no one
treatment being 100% effective in all patients. Further research is critical to
understanding the factors underlying such variability and underlying mechanisms, to
guide recommendations for combined treatments. There is also room for research into
novel treatment options.
Keywords: myopia control, optical, pharmacological, behavioral, surgical
1. GENERAL INTRODUCTION
This article encompasses various interventions in current usefor controlling myopia progression in children, organized
under three broad categories: optical, pharmacological and
environmental (behavioral). Surgical interventions aimed at
stabilizing highly myopic eyes are also covered as a fourth
topic. In each case, current treatments, as well as those in
limited use and/or subjected to clinical trial, are considered.
The still climbing myopia prevalence figures worldwide,
including of high myopia, and the association between high
myopia and sight-threatening ocular pathologies, provides
strong motivation for research into underlying mechanisms
and effective therapies that can limit ocular elongation, with
the hope that the incidence of such pathologies also may be
limited. Other articles in this special issue of Investigative
Ophthalmology and Visual Science offer comprehensive
coverage of the experimental animal model literature and
approaches for monitoring progression, with best practice
recommendations in relation to assessing treatment outcomes
(see accompanying IMI – Clinical Management Guidelines
Report).1 Thus in this article, coverage has been limited to a
brief background overview of the treatments themselves,
evidence for efficacy, with emphasis on high-quality random-
ized clinical trials, adverse effects, and future directions for
research.
Copyright 2019 The Authors
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2. OPTICAL INTERVENTIONS FOR MYOPIA
MANAGEMENT
2.1 Introduction
Optical interventions for controlling myopia have an extensive
history, with early clinical studies largely based around
spectacles aimed at altering the near visual experience. Clinical
studies involving contact lens–based treatments are largely
limited to the 21st century, with studies demonstrating optical
defocus-driven regulation of eye growth in animal models
helping to reawaken interest in, and drive new optical
approaches to myopia control. Specifically, as demonstrated
first in young chicks, imposed myopic defocus is known to
slow eye growth, whereas the converse is true for hyperopic
defocus (i.e., eye growth accelerates).2 This report summarizes
the results from clinical studies using spectacles, contact
lenses, and orthokeratology (OK). The evidence contained in
relevant published studies has been evaluated and recommen-
dations for using optical strategies for myopia control
provided, based on the quality of reported results and the
evidence.
2.2 Spectacles
The utility of using spectacle lenses for slowing myopia
progression has many advantages over other forms of myopia
management, as they are easy to fit, are mostly well accepted
and tolerated, are affordable by most, and are minimally
invasive. The various spectacle lens–based approaches aimed
at slowing the progression of myopia include both standard
and customized single-vision (SV) lens designs, as well as
bifocal and progressive spectacle lenses.
There is equivocal evidence concerning whether full
correction with SV spectacles causes faster myopic progression
than full correction with soft contact lenses.3–7 The evidence
would suggest that if that is the case then the difference is
likely clinically irrelevant.
2.2.1 Undercorrection With Spectacles. Undercorrec-
tion to slow the progression of myopia has been in practice for
many years and was originally considered to slow the
progression of myopia by reducing the accommodative
demand during near tasks. The accumulating reports of slowed
eye growth in response to experimentally imposed myopic
defocus in animal models,2,8 also led to parallels being drawn
with the myopic defocus experienced during distance tasks
with undercorrection, and thus speculation about this poten-
tial additional benefit.
An early nonrandomized trial of undercorrection, conduct-
ed in 1960s,9 found this treatment to slow the progression of
myopia. More recently (since 2000), well-designed, random-
ized controlled trials (RCTs) examining undercorrection for
distance (byþ0.50 toþ0.75 diopters [D]) over 1.5 to 2.0 years
found this treatment to either increase myopia progression or
have no benefit, when compared with myopia progression in
fully corrected SV spectacle wearers (Table 1).1012 Although
all trials involved relatively young children at an age when
progression is common, the trials were only small to moderate
in size. However, the latter weakness does not explain the
consistent trend of faster progression in undercorrected eyes
observed in some studies. Nonetheless, although another
larger, albeit nonrandomized trial also found no significant
difference between comparable treatment groups, curiously,
myopia progression significantly decreased with increasing
undercorrection.13 The latter trend is also consistent with
results from a recent study comparing myopia progression in
uncorrected and fully corrected 12-year-old children; this study
found slower progression in the former group, the latter effect
increasing with the amount of undercorrection.14 The possi-
bility that the lack of sharp distance vision with under-
correction strategies may lead to behavioral changes, such as
reduced outdoor activities in some children, thereby favoring
myopia progression, warrants investigation, although the
contrasting study outcomes suggest additional factors are at
play.
2.2.2 SV Peripheral Defocus-Correcting Lenses. Find-
ings from animal studies,2 including monkeys,29 offer strong
evidence for contributions by the peripheral retina to eye
growth regulation and refractive development (see accompa-
nying IMI – Report on Experimental Models of Emmetropiza-
tion and Myopia).30 In addition, a number of studies have
reported relative peripheral hyperopia in myopic eyes when
fully corrected with SV spectacles.31–33 Thus, it has been
hypothesized that the hyperopic defocus experienced by the
retinal periphery may drive further axial elongation.
Three novel spectacle lens designs aimed at reducing the
relative peripheral defocus were tested in an RCT designed to
evaluate this notion.27 The results were generally disappoint-
ing, with no significant differences in myopia progression
between the groups observed. In subgroup analysis, one of the
lens designs (Type III) that was specific to right and left eyes
demonstrated a small benefit (of 0.25 D), compared with SV
spectacles in younger children with parental myopia. Likewise,
a recent trial involving Japanese children found no benefit of
the MyoVision lens, a positively aspherized design,34 and in a
further test of this treatment approach, no benefit was found
by combining a peripheral defocus correction with a
progressive addition zone for near work.28
2.2.3 Bifocal Spectacles. Traditional rationales for pre-
scribing bifocal spectacles for myopia control include reducing
or eliminating lags of accommodation during extended near
work, lags being a potential source of hyperopic defocus.
Reducing accommodative demand is another, with the
associated reduction in ciliary muscle tension potentially
reducing stress on the overlying sclera. All multifocal (MF)
lens designs, including bifocal lens designs, also induce relative
myopic shifts in peripheral refractive errors, at least in superior
retinal field.31 Many of the bifocal spectacle trials, with the
exception of a single trial involving executive bifocal lenses,26
were conducted before 2000, and mostly in 1980s.
There have been a number of RCTs involving bifocal
spectacle lenses. One such study,15 which involved children
with near point esophoria followed over 2.5 years, reported a
modest (0.25 D), albeit statistically significant, reduction in
progression with a 28-mm flat top bifocal lens compared with
SV spectacles. Vitreous chamber growth was also significantly
reduced, although the change in axial length (AL) was not.
However, in a previous 3-year trial, mean rates of progression
were less for SV spectacles worn on a continuous basis
compared with bifocal spectacles or SV spectacles for distance
only (1.46 D, continuous SV versus1.58 D, bifocal (þ1.75 D,
straight top), versus 1.88 D, SV spectacles for distance
only).17 Similarly, no significant differences in myopia progres-
sion were observed in the Houston Myopia study,18 between
groups wearing either of two executive bifocal lens designs
(þ1.00 orþ2.00 D add) or SV lenses. Retrospective analysis of
longitudinal data from three optometry practices also found no
significant differences in myopia progression between those
wearing SV spectacles and bifocal spectacles.16
The above results stand in sharp contrast to those of a
relatively recent RCT involving two high-set executive bifocal
lens designs (þ1.50 D add alone andþ1.50 D add with 3D base-
in prism), both of which significantly reduced myopia
progression in children older than 3 years compared with SV
spectacles (1.25 D [bifocals] versus 1.01 D, [prismatic
bifocals] versus 2.06 D [SV]), in children with progressing
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myopia). Overall, the magnitude of change was similar
between the two bifocal groups, except for children with
low lags of accommodation, for whom the prismatic bifocal
lenses had a greater benefit.26 The investigators speculated that
for children with low lags, both convergence and lens-induced
exophoria were reduced by the base-in prism; the latter effects
presumably led to improved compliance.
2.2.4 Progressive Addition Spectacles (PALs). Of all the
spectacle interventions assessed for their efficacy in slowing
the progression of myopia, PALs have been the most studied.
As with bifocal spectacles, the rationale for their use has been
to reduce the accommodative demand and/or reduce accom-
modative lag during near tasks.
Leung and Brown19 proposed the use of PALs as an
alternative to bifocal lenses, which were considered to not
adequately control defocus for all distances. Their clinical trial,
which compared myopia progression withþ1.50 andþ2.00 D
PALs and SV lenses over 2 years, found significantly reduced
myopia progression relative to that with SV lenses with both
þ1.50 D (0.47 D difference) and þ2.00 D PAL (0.57 D
difference).19 However, this study was not fully randomized
and later RCTs conducted in the United States, Hong Kong,
China, and Japan (using either þ1.50 or þ2.00 D add power
compared with SV lenses), found that although PALs signifi-
cantly reduced myopia progression, often the difference from
progression with SV lenses was <0.25 D and not considered
clinically significant.2023 Larger treatment effects were ob-
served with theþ2.00 D PALs used in children with both high
accommodative lag and near esophoria (of 0.28 D over 3 years)
but here again, they were not deemed to be clinically useful.24
Likewise, the results from a shorter (1-year) study, which
specifically targeted children with high accommodative lag
and/or near esophoria, indicated a positive, but clinically
questionable treatment effect with PALs (0.18 D after 1 year of
lens wear), although a relationship between superior retinal
defocus and the change in on-axis refractive error was noted,
with superior myopic defocus associated with less central
myopia progression.25,31
2.3 Contact Lenses
2.3.1 SV Soft Contact Lenses. Most soft lenses with
spherical surfaces have negative spherical aberration in
negative powers.35 At first glance, this might appear to
produce a hyperopic shift in the peripheral refraction, which
could encourage axial growth of the eye, compared with, for
example, an SV spectacle lens that has little spherical
aberration.36 However, Atchison37 has shown with optical
modeling that spherical contact lenses will produce more
peripheral myopic shift than spherically surfaced spectacle
lenses. As a result, one may hypothesize that if a myopic
peripheral refraction retards myopia progression, then SV soft
contact lenses may be protective against myopia progression
compared with SV spectacles.
In a retrospective chart review, Andreo5 examined the
effects of soft contact lenses on myopia in patients aged 14 to
19 years over a 13-month period. There was no statistically
significant difference in the rate of myopia progression
between those who wore contact lenses full-time and those
wearing spectacles. To-date, there have been two prospective,
randomized studies comparing the rate of myopia progression
between contact lens and spectacles wearers. Horner et al.4
examined 175 adolescents between the ages of 11 and 14 years
and found no difference in mean spherical equivalent
refractive errors, between spectacle and soft contact lens
wearers after 3 years. Walline and coworkers3 examined
myopia progression over 3 years in 484 children aged between
8 and 11 years and concluded ‘‘soft contact lens wear by
children does not cause a clinically relevant increase in AL,
corneal curvature, or myopia relative to spectacle lens wear.’’
Fulk and colleagues6 permitted a small cohort of subjects to
choose either soft contact lenses or spectacles to wear after a
clinical trial of bifocal spectacles for myopia control treatment.
They found that myopia progressed at an age-adjusted average
rate of 0.74 D in 19 children who switched to soft contact
lenses compared with 0.25 D for 24 children remaining in
spectacles (P < 0.0001), some of which was accounted for by
steepening of the corneal curvature in the contact lens
wearers. Marsh-Tootle et al.7 reported on 286 participants
from the COMET study who wore their original spectacle
lenses for 6 years (n¼199), or wore soft contact lenses most or
all the time between the 5- and 6-year visits (n¼ 87). The two-
year myopia progression was evaluated in a subset of 183
participants who wore the same lens type for an additional year.
Mean (6 SD) myopia progression after 1 year was significantly
higher (P¼ 0.003) in the contact lens group (0.28 6 0.33 D)
than in the spectacle group (0.14 6 0.36 D), and remained
higher after 2 years in the two subsets (0.52 6 0.46 D versus
0.25 6 0.39 D, P < 0.0001). Corneal curvature remained
unchanged in both groups. They concluded that children
switching from spectacles to contact lenses experienced a
small, statistically significant but clinically inconsequential
increase in myopia progression over this time.7
Low oxygen transmissibility (Dk/t) lenses, worn under
extended wear conditions have also been linked to greater
myopic progression compared with high Dk/t lenses worn
under the same conditions.38,39 However, the higher Dk/t
lenses were manufactured from a higher modulus (silicone-
based) material and caused corneal flattening; as the lenses
also have minimal spherical aberration, it is not clear which
factors may have influenced myopia progression in this study.38
In conclusion, there is no substantial evidence in the
literature that conventional soft contact lens wear leads to
either slower or faster myopia progression than spectacle wear.
2.3.2 Gas-Permeable Contact Lenses (GP). There have
been suggestions over several decades that alignment-fit GPs
(not OK design), can slow myopia progression in children.40–42
However, most of these studies have important limitations in
their study design.43,44 More recent, well-conducted studies
showed that the use of these lenses did not impact axial
elongation and that the apparent control of myopia progres-
sion observed with GPs was most likely induced by corneal
flattening.44,45
2.3.3 Soft Multifocal (MF) Contact Lenses. Soft MF
contact lenses are increasingly used for controlling myopia
progression in children, although some designs were originally
intended for use by presbyopes and are used off-label.
Although they come in many designs, only center-distance
designs have been formally investigated in the context of
myopia control. In these designs, the peripheral region of the
lens has relatively more positive (plus) power, incorporated as
a gradual increase toward the periphery (progressive design)
or presented in distinct zones (concentric ring design). The
lens design is reflected in the labeling: bifocal, MF, gradient,
progressive, or positive spherical aberration–inducing lenses.
In most cases, the lenses are intended to provide clear distance
vision, while imposing myopic defocus on the more peripheral
retina as a putative stimulus to slow eye growth. However,
higher-order aberrations, including spherical aberration, are an
inherent feature of most MF lens designs, with potential
benefits to near vision in presbyopes; these aberrations likely
also contribute to the myopia control effect of these lenses.46
To-date, results from nine soft MF contact lens trials have
been published.47–55 The main features of these trials are
summarized in Table 2. In brief, the trials include five RCTs
with bilateral contact lens treatments47,49–51,55 and one
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contralateral control RCT.48 Only three of the trials47,55,56 used
commercially available contact lenses. Three trials used
concentric ring designs, with the other six trials using
progressive power designs. Five of the studies followed
subjects for 2 years,50–52,54,55 with one of them involving a
crossover design.50 SV contact lenses were used as control
treatments for most of the studies (7 of 9), with the remaining
two studies using SV spectacles. All studies had similar
boundary conditions for recruited subjects; ages ranged from
7 to 18 years, with low to moderate myopia (average SE:
approximately2 D; range: –0.50 to –6.00 D) (Table 2). Across
all studies combined, 76% of subjects completed the trials.
Based on sample size–weighted averages, the eight trials
published over the 2011 to 2016 period showed a 38.0%
slowing of myopia progression and a 37.9% slowing of axial
elongation with MF soft contact lens interventions (see Figure).
Some studies showed greater apparent slowing of myopia
progression than of axial elongation,52,54 and others, greater
apparent slowing of axial elongation than of myopia progres-
sion,48,49 and some, approximately matched slowing of myopia
progression and axial elongation.47,50,51,53,55 Interestingly,
concentric ring designs showed better control over axial
elongation than progressive designs (44.4% versus 31.6%),
whereas their effects on myopia progression were similar
(36.3% versus 36.4%). The most recently published compre-
hensive data for the MiSight lens are from a randomized
controlled but not masked trial.55 Reductions in myopia
progression and axial elongation at the end of a 2-year trial
period, of 39% and 38% respectively, are similar to the group
averages reported above, although the efficacy of the MiSight
lens could have been slightly overestimated as the subjects in
the treatment arm were slightly older (by approximately 1
year). Nonetheless, significant reductions in myopia progres-
sion were also observed at 1-, 2-, and 3-year visits in a larger, 3-
year RCT of the same lens.57 The dropout rates for the MiSight
and SV (control) lenses over 3 years in the latter study were
similar, 26% and 24%, respectively.58
Only two of the eight trials examined the potential
influence of peripheral refractive errors on myopia progres-
sion.52,53 Noteworthy, both trials used SV spectacle lenses as
opposed to SV contact lenses as controls. Sankaridurg et al.53
reported a significant correlation between the relative
peripheral hyperopia at 30 and 40 degrees nasal and 40
degrees temporal, measured with correcting lenses in place,
and myopia progression. Likewise, Paune et al.52 reported a
significant correlation between the relative peripheral
refractive errors at 30 degrees nasal and temporal and axial
elongation over the first year of treatment. In the crossover
‘‘contralateral control’’ trial of Anstice and Phillips,48 the
eyes wearing the MF soft contact lenses showed slower
myopia progression and axial elongation relative to their
fellows, in both phases of the trial. Furthermore, under the
monocular MF lens condition of this study, accommodative
responses to near tasks were consistent with accommodation
being driven by the center-distance zone of the MF lenses,
the implication being that accommodative lags would have
been minimally affected. However, two other studies
reported positive benefits on accommodative errors in the
presence of MF soft contact lenses (i.e., decreased accom-
modative lags46 and accommodative leads59). An increase in
higher-order aberrations and a relative decrease in peripheral
hyperopia through the MF contact lenses were also reported
in the study of Paune and colleagues,46 who speculated on
the potential positive benefits for myopia control of both of
these optical effects.
2.3.4 Orthokeratology. OK, also known as corneal
reshaping therapy, involves reshaping of the cornea to reduce
myopic refractive errors.60–63 The development of speciallyT
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designed reverse geometry rigid GP lenses has revolutionized
OK, by allowing sufficient reshaping of the cornea to be
achieved with overnight wear. The reshaping is believed to be
due to a redistribution of corneal epithelial cells following
initial compression.64 Although the initial goal of such
therapies was to eliminate the need for daytime optical
corrections, OK has proven to be effective in slowing myopia
progression. OK also has been shown to induce relative
myopic shifts in peripheral refractive errors in all meridians,65
consistent with the most popular hypothesis for this myopia
control effect,66 although a role for altered higher-order
aberrations cannot be excluded.67,68
Most studies on the effectiveness and reliability of OK for
myopia control have focused on children,60,69–75 with only
limited reports on effects in adults.63 They include two RCTs in
children,60,72 one randomized crossover trial,61 and several
longitudinal nonrandomized clinical trials. Details of these
studies are summarized in Table 3.
In the earliest of these trials, the Longitudinal Orthokera-
tology Research in Children (LORIC) study,69 35 children aged
7 to 12 years and undergoing OK treatment, were monitored
over 24 months. Comparative data were obtained from 35
historical controls (age-, sex-, and initial-spherical equivalent
refractive error–matched children wearing SV spectacles).20
Axial elongation in the OK group over the 2-year trial period
was approximately half that in the control group (0.29 vs. 0.54
mm), with the respective increases in vitreous chamber depth
largely accounting for this difference (0.23 vs. 0.48 mm).
Following the LORIC study, other quasi-experimental studies
on children with low to moderate myopia were conducted
with similarly positive outcomes70,71,74,75; reported levels of
control ranged from 32% to 55%, when changes were
compared against those in children wearing either SV
spectacles or SV soft contact lenses.
Results from the two published RCTs provided further
evidence for the efficacy of OK as a myopia control treatment.
In the first trial, the Retardation of Myopia in Orthokeratology
(ROMIO) study,72 axial elongation was reported to be slowed
by an average of 43%, with treatment effects being propor-
tionately larger in younger, more rapidly progressing myopic
children (7–8 years: 20% versus 65% [control]) than in older
children (9–10 years: 9% versus 13% [control]). Higher myopes
(5.75 D or above) were recruited into a second trial, the High
Myopia–Partial Reduction Orthokeratology (HM-PRO) study60
and randomly assigned into partial reduction (PR) OK and SV
spectacles groups. As the PR OK treatment targeted a 4.00-D
reduction only, treated subjects needed to wear SV spectacles
to correct residual refractive errors during the day. Nonethe-
less, here also, axial elongation in the PR OK group was 63%
less than that of the control group.
In a more recent study, the effect on ‘‘myopia progression’’
of OK was compared against conventional GP lenses using a
novel experimental design,61 in which one eye of each subject
wore an OK lens and the other eye, a GP lens, each for two 6-
month periods, with the lens type worn by each eye switched
at the end of the first 6 months after a washout period of 2
weeks. The eye wearing GP lenses thus acted as a ‘‘self’’
control. The subjects were of East Asian ethnicity, aged 8 to 16
years. No increases in AL over either the first or second 6-
month period were recorded for eyes subjected to OK,
compared with increases of 0.04 and 0.09 mm respectively
in eyes wearing the GP lenses. Note, however, that even the
latter changes are small relative to changes recorded with
control treatments in other studies.
All of the above studies used spherical design OK lenses and
thus were confined to children with low astigmatism.
However, a subsequent 2-year trial, the Toric Orthokeratology
Slowing Eye Elongation (TO-SEE) study, involving children with
moderate to high astigmatism and OK lenses with toric
peripheries,73 reported axial elongation to be 52% less than
in their control group who wore SV spectacles.
Two relevant meta-analyses by Si et al.76 and Sun et al.77
have confirmed the effectiveness of OK for myopia control,
although Si et al.76 recommended further research, given that
five of the seven studies included in their meta-analysis were
from Asia.
A few studies suggest that early termination of OK
treatment might lead to a greater increase in axial elongation
and myopia in children,61,78,79 although this has not been
found to be the case in university students with adult-onset,
progressive myopia.80 Some studies also suggest that relative
treatment efficacy may decrease with time.75,81,82 Reduced
treatment efficacy has been linked to lower baseline myo-
pia,69,82–84 although there may be confounding factors not
accounted for. The magnitude of the treatment-induced power
change has also been reported to impact myopia control,
independently of baseline myopia,85 although not in all
studies.71,72,75,86,87 On the other hand, larger pupil diameters,
deeper anterior chambers, and steeper, more prolate corneas
FIGURE. Percent slowing of change in refractive error and axial elongation for soft MF contact lens myopia control studies published in the peer-
reviewed literature.
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are among ocular parameters that have been linked to slower
axial elongation in children.88
2.3.5 Visual and Ocular Side Effects. Vision-related
complaints tend to be defocus-related in origin across all
optical interventions, and correctible with appropriate adjust-
ment to prescriptions, although substantial changes to resolve
the such complaints also may lessen the likelihood of adequate
myopia control. Significant ocular side effects are largely
limited to contact lenses used for myopia control. In OK
wearers, pigmented ring formation60,90 and altered corneal
nerve pattern (fibrillary lines)91,92 have been reported,
although none of these changes appear to have adverse clinical
ramifications. A number of cases of microbial keratitis
associated with OK have been reported in the literature, more
frequently encountered in the early years of OK,93,94 with
contact lens storage cases being one potential source of
contamination.95 Nonetheless, Bullimore and colleagues96
compared the incidence of microbial keratitis associated with
OK in children and adults and concluded that, within the limits
of their study, there is no difference in the risk of microbial
keratitis with OK and other overnight contact lens modalities,
although the risk is higher for overnight compared with daily
wear.
3. PHARMACOLOGICAL CONTROL OF MYOPIA
3.1 Introduction
In relation to pharmacological control of myopia progression,
to-date topical atropine has dominated both clinical trials and
clinical practice, where it is now used widely as either an
approved product or off-label. Atropine is a nonselective
irreversible antimuscarinic antagonist, with a long history of
use in ophthalmology as a potent and long-acting mydriatic and
cycloplegic agent. Clinically, it is used as a diagnostic aid in the
assessment of refractive errors in very young children,97 to
penalize the preferred eye in therapy for amblyopia,98 and to
immobilize the iris and ciliary muscles as a component of
therapy for uveal inflammatory conditions such as iritis.99 Its
use to treat myopia dates back to the 1960s.100103
The earliest cohort studies involving topical atropine were
published in the 1970s.100103 Since that time, numerous
retrospective and cohort studies have been published.104112
The first randomized controlled trials (RCTs) to be published
are those by Yen et al. (1989)113 and Shih et al. (1999).114 More
recently, two large, back-to-back trials were undertaken in
Singapore: the Atropine for Treatment Of Myopia studies
(ATOM1 and 2),115119 followed by two smaller studies in
China by Yi et al. (2015)120 and Wang et al. (2017),121 and a
very recent larger trial in Hong Kong.122 Table 4 summarizes
details of these seven trials, including the tested atropine
concentrations, which vary widely, from as low as 0.01% to
1.0%. Two other antimuscarinic drugs appear in these studies:
tropicamide, which is a short-acting drug and was used as a
control treatment, and cyclopentolate, which has an interme-
diate duration of action and was tested for its efficacy as a
myopia control agent.
Other pharmacological approaches trialed for myopia
control include topical timolol, a nonselective beta-adrenergic
antagonist, and oral 7-methylxanthine (7-MX), an adenosine
antagonist. The latter was approved for use in Denmark, as
pharmacy-compounded tablets, with reimbursement from the
Danish National Health Insurance for patients up to 18 years of
age, after a small clinical trial of 7-MX in that country123; 7-MX
is also generated by metabolism in the body from caffeine and
theobromine, which are both ingredients of dark chocolate. To-
date there have been no follow-up trials in other countries,
although it remains a drug of interest, with related on-going
studies in the monkey myopia model.124
Although recommendations for the use of ocular hypoten-
sive drugs for myopia control appear in a number of early
publications, including that by Curtin (1985),125 well-de-
scribed clinical trials of these agents are limited, although
there are reports of positive treatment outcomes for epineph-
rine,126,127 labetolol,128 a combination of pilocarpine and
timolol,129 and timolol alone.128 Denmark was the site of the
largest RCT of twice-daily topical 0.25% timolol for myopia
control, by Jensen (1991).130 The driving principle for this
approach is biomechanical (i.e., to lower IOP as a method of
slowing ocular elongation). Topical timolol is widely available
in many countries as a topical ophthalmic drug, approved for
the treatment of open angle glaucoma.
Reviews covering pharmacological interventions for myopia
control include one focused on primary research,131 a
Cochrane review,56 and a more recent one focused on
atropine.132 In this article, results of relevant meta-analyses
are also presented.
3.2 Atropine
3.2.1 Changes in Spherical Equivalent Refractive
Error as an Outcome Measure. Based on changes in
spherical equivalent refractive error as the outcome measure
all studies have shown that atropine slows myopia progression.
Bedrossian (1971)100 in an early study of 150 children aged 7 to
13 years reported no myopia progression in 75% of eyes treated
daily with 1% atropine over a 1-year period compared with
only 3% of controls. Similarly another early study by Gimbel
(1973)103 in which 279 children received 1% atropine over 3
years reported a 66% reduction in myopia progression
compared with that of 572 controls (0.41 vs. 1.22 D).
The first two randomized controlled trials of atropine, both
published in the 1990s, also reported very good control over
myopia progression in children, with reductions exceeding
60% reported for the highest, 1% concentration. In the first
randomized controlled trial by Yen and colleagues (1989),113
247 children aged 6 to 14 years received either topical 1%
atropine, 1% cyclopentolate, or saline drops over a 1-year
period. They reported 76% and 36% reductions in myopia
progression in the groups treated with atropine and cyclopen-
tolate, respectively, compared with the group treated with
saline, although unfortunately, there was a large loss to follow-
up (61%). In the second randomized controlled trial by Shih
and colleagues (1999),114 200 children aged 6 to 13 years were
treated with 0.5%, 0.25%, or 0.1% atropine over a 2-year period;
reported reductions in myopia progression were 61%, 49%,
and 42%, respectively, compared with children treated with
0.5% tropicamide as the control treatment.
The ATOM1 and 2 studies, which were performed between
1996 and 2013, involved 400 children, aged 6 to 12 years,
randomized in each case, to atropine 1% and placebo in a 1:1
ratio in ATOM1, and to 0.5%, 0.1%, and 0.01% atropine in a
2:2:1 ratio in ATOM2.115119 Both trials involved a 2-year
treatment period. On entering the studies, children had low to
moderate myopia; baseline spherical equivalent refractive
errors ranged between 1.0 and 6.0 D in ATOM1, and
between2.0 and6.0 D in ATOM2. Overall, the profiles of the
participants in these two trials were very similar, although
slightly younger, with lower myopia in the first compared with
the second trial (9.2 vs. 9.6 years; 3.4 vs.4.7 D).116,118 The
reported mean progression rates for these trials were 0.2,
0.3,0.4, and0.5 D for the four atropine groups (1%, 0.5%,
0.1%, and 0.01%) compared with 1.2 D in the placebo
group,115119 amounting to reductions in myopia progression
compared with the latter group of approximately 80%, 75%,
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67%, and 58%, respectively. Loss to follow-up over the 2-year
treatment periods was 13% and 11% for ATOM1 and ATOM2,
respectively.
Analysis of the changes in the ATOM1 study, year by year,
revealed a hyperopic shift in the 1% atropine group of þ0.03
versus 0.79 D in the control arm.118 The comparable values
for the 0.5%, 0.1%, and 0.01% atropine treatment groups
included in ATOM2 are 0.17, 0.31, and 0.43 D respective-
ly.116 Thus, myopia progression rates appear to directly reflect
the atropine concentration used, decreasing with increasing
concentration. However, dose-dependent differences were not
apparent over the second year of the trial, with all three
concentrations achieving similar slowing of myopia progres-
sion. The net increases in myopia over the 2-year trial period
were0.49,0.38, and0.30 D for the 0.01%, 0.1%, and 0.5%
concentrations, respectively.116
Two of three more recent RCTs involved relatively high
concentrations of atropine, being 1% (n¼ 126) and 0.5 % (n¼
132) in the studies by Yi et al. (2015)120 and Wang et al.
(2017),121 respectively. Both reported hyperopic shifts in the
atropine-treated groups, presumably reflecting, at least in part,
the enduring strong cycloplegic action of this treatment, while
continued progression in control groups over the same period
of time was observed (i.e.,þ0.3 vs.0.9 D andþ0.5 vs.0.8 D).
Three lower concentrations of atropine, 0.01%, 0.025%, and
0.05%, were tested in the most recent of these studies, by Yam
et al. (2018) (n ¼ 438),122 who reported a concentration-
dependent reduction in myopia progression, with the highest
concentration approximately halving the rate of axial elonga-
tion, as compared with the placebo control. All concentrations
were well tolerated.
Although retrospective studies typically lack the same level
of control of key study design variables as RCTs, overall their
results are consistent with those of the RCTs just described.
Several retrospective, cohort studies have tested higher, 0.5%
to 1.0% concentrations of atropine, reporting treatment effects
ranging from 70% to 100%.104106,108,109 In one of four studies
involving lower concentrations of atropine, children treated
with 0.025% atropine over 22 months were reported to
progress by an average of 0.28 D per year, compared with
0.75 D in untreated children (a reduction of 63%).107
Similarly, Fang and colleagues (2010),111 using the same
0.025% atropine concentration with ‘‘premyopic’’ children
(spherical equivalent refractive error: þ1 to 1 D), reported a
reduction in incident myopia and reduced progression
compared with controls (21% versus 54%, 0.14 vs. 0.58
D). Wu and colleagues110 also noted reduced progression with
atropine treatments, although interpretation of their study
findings is complicated by the variation in atropine concentra-
tions used to treat individual patients over the 4.5-year
monitoring period, between 0.05% and 0.1%; the overall mean
progression was0.23 D per year, compared with0.86 D per
year in historical ‘‘controls.’’ A surprisingly low average myopia
progression of0.1 D per year was reported for 0.01% atropine
in the only retrospective study involving this concentration,
referenced against a control rate of 0.6 D per year,112
although interestingly, this study included children of both
Asian and Caucasian ethnicity.
3.2.2 Changes in AL as an Outcome Measure. Fewer
studies have included AL as an outcome measure although
arguably it more accurately reflects the treatment effect, being
free from the confounding effect of cycloplegia, which affects
refractive error data (see accompanying IMI – Clinical Myopia
Control Trials and Instrumentation Report).133 Notably, cyclo-
plegic agents, by reducing ciliary muscle tone, reduce manifest
myopia. Indeed, the latter effect likely accounts for, at least in
part, the more promising results of lower concentrations of
atropine, when expressed in refractive error terms, as
compared with AL changes, given that the ciliary muscle is
readily accessible to topically applied drugs. It can be further
argued that AL changes are more clinically relevant, given that
many of the pathological complications of myopia are by-
products of excessive eye elongation (see accompanying IMI –
Defining and Classifying Myopia Report).134
TABLE 4. Summary of Design and Key Results From Randomized Trials Involving Topical Atropine for Myopia Control
Study (Country)
Size;
Duration,
y Treatments
Age
Range,
y
Baseline
Age, y*
Myopia
Range,
D
Average
Myopia,
D*
Change
in SER*#
Change
in AL, mm*#
Loss to
Follow-Up,
%
Yen et al. (1989)113
(Taiwan)
247; 1 A 1% and 6, 14 10.5 0.5, 4 1.5 (0.9) 0.2 D (76%) – 61
Cyclo 1% 10.0 1.4 (0.8) 0.6 D (37%)
vs. Saline 10.4 1.6 (0.9) 0.9 D
Shih et al. (1999)114
(Taiwan)
200; 2 A 0.5% 6, 13 9.8 0.5, 7 4.9 (2.1) 0.04 D/y (61%) – 7
A 0.25% 9.7 4.2 (1.7) 0.45 D/y (49%)
A 0.1% 8.9 4.1 (1.5) 0.47 D/y (42%)
vs. Trop 0.5% 8.3 4.5 (1.8) 0.61 D/y
Chua et al. (2006)118
(Singapore)
400; 2 A 1% 6, 12 9.2 1, 6 3.6 (1.2) 0.3 (0.9) (77%) 0.02 (0.35) (105%) 13
vs. Placebo 9.2 3.4 (1.4) 1.2 (0.7) 0.38 (0.38)
Chia et al. (2016)119
(Singapore)
400; 2 A 0.5% 6, 12 9.5 (1.5) 2, 6 4.5 (1.5) 0.3 (0.6) (75%) 0.27 (0.25) 11
A 0.1% 9.7 (1.6) 4.8 (1.5) 0.4 (0.6) (67%) 0.28 (0.28)
A 0.01% 9.7 (1.5) 4.7 (1.8) 0.5 (0.6) (58%) 0.41 (0.32)
Wang et al.
(2017)121 (China)
126; 1 A 0.5% 5, 10 9.1 (1.4) 0.5, 2 1.3 (0.4) 0.8 (160%) 1.1 (300%) 13
vs. Placebo 8.7 (1.5) 1.2 (0.3) 2.0 þ0.50
Yi et al. (2015)120
(China)
140; 1 A 1% 7, 12 9.9 (1.4) 0.5, 2 1.2 (0.3) þ0.3 (0.2) (138%) 0.03 (0.07) (109%) 6
vs. Placebo 9.7 (1.4) 1.2 (0.3) 0.9 (0.5) 0.32 (0.15)
Yam et al. (2018)122
(Hong Kong)
438; 1 A 0.05% 4, 12 8.45 (1.81) 1 (min) 3.98 (1.69) 0.27 (0.61) 0.20 (0.25) 12
A 0.025% 8.54 (1.71) 3.71 (1.85) 0.46 (0.45) 0.29 (0.20)
A 0.01% 8.23 (1.83) 3.77 (1.85) 0.59 (0.61) 0.36 (0.29)
vs. Placebo 8.42 (1.72) 3.85 (1.95) 0.81 (0.53) 0.41 (0.22)
Cyclo, cyclopentolate; min, minimum; Trop, tropicamide.
* Standard deviations in brackets.
# Percent change from placebo.
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In the ATOM1 study, in which AL was measured using A-
scan ultrasonography, changes in AL at the end of years 1 and 2
of 0.14 and 0.02 mm, respectively, were reported for
children treated with 1% atropine compared with 0.20 and
0.38 mm in the placebo group.118
In the ATOM2 study, in which ALs were measured using a
noncontact method (IOL Master; Zeiss, Oberkochen, Ger-
many), changes in AL over the first year were 0.11, 0.13, and
0.24 mm in the 0.5%, 0.1%, and 0.01% atropine concentrations
respectively.116 Equivalent values for the total 2-year study
period were 0.27, 0.28, and 0.41 mm. Without a control group,
the true effect of lower doses of atropine on axial elongation is
difficult to evaluate, given that there was also no difference
between changes in the group treated with 0.01% atropine and
historical controls in the ATOM1 study.118 However, although
AL increases with the lowest, 0.01% concentration was greatest
over the first year in the ATOM2 study, the changes with the
0.5%, 0.1%, and 0.01% concentrations were more similar over
the second year of the study (0.16, 0.15, and 0.17 mm,
respectively).116
Of the two more recent RCTs, one also used A-scan
ultrasonography, as in ATOM1; over the 1-year of this study, the
mean change in AL was0.03 mm in the 1% atropine treatment
group, compared with 0.32 mm in the control group.120 In the
second RCT, which involved 0.5% atropine, AL data are not
provided in an easily accessible form, although there appears
to be a surprising reduction over the 1-year study period in AL
of approximately 0.4 mm in the treated children compared
with an increase of 0.5 mm in the control group.121
3.2.3 Poor and Nonresponders to Atropine and Time-
Dependent Reductions in Efficacy. Although the studies
just described confirm the efficacy of topical atropine as a
myopia control treatment, the range of responses within
treatment groups also implies that some individuals respond
less well and there is also evidence that treatment efficacy may
change over time.
In the early studies by Bedrossian,100,101 5% to 25% of
children treated with 1% atropine for 1 year were reported to
exhibit continued myopia progression. Likewise, for the same
treatment regimen, progression of more than 0.5 D was
reported in 22% of children in the Yen et al. study113 and 12%
of children in the ATOM1 study.135 Nonetheless, results from
the Shih et al. study114 imply a related dose-dependence, with
4%, 17%, and 33% of children showing myopic progression
>1.0 D, with 0.5%, 0.25%, and 0.1% atropine, respectively,
after 1 year of treatment (compared with 44% of those treated
with 0.5% tropicamide). Likewise, for the ATOM1 and ATOM2
studies, 4%, 7%, 11%, and 18% of children recorded progres-
sion rates of >1 D after 1 year of treatment with 1.0%, 0.5%,
0.1%, and 0.01%, respectively. Poor responders, as identified
through multivariate analysis, tend to be younger, to be more
myopic at baseline, to start wearing spectacles at a younger
age, and to have myopic parents.135 Note, however, that the
trends evident after year 1 in the ATOM1 and ATOM2 studies
were not sustained over the total 2-year treatment period due
to loss of efficacy with the higher doses over the second year of
treatment; thus, after 2 years, progression of >1 D was
reported in 14%, 15%, 17%, and 17% of children treated with
1.0%, 0.5%, 0.1%, and 0.01% atropine, respectively.116,118
Nonetheless, although the results of the ATOM studies point
to some loss of treatment efficacy with time, at least with the
higher concentrations of atropine, those from the study by Wu
and colleagues,110 which involved concentrations between
0.05% and 0.1%, suggest that treatment effects can be
maintained for up to 4.5 years.
3.2.4 Rebound Effects After Termination of Atropine
Treatment. The first evidence of apparent rebound effects on
myopia progression after the termination of atropine treatment
comes from the study of Bedrossian (1979),101 which involved
monocular 1% atropine, with treatment being alternated
between right and left eyes on a yearly basis for 4 years;
progression rates for eyes under treatment ranged from 0.17 to
0.29 D, substantially lower than those in fellow, untreated eyes
of 0.81 to 0.91 D. However, it is not possible to judge whether
these values represent exaggerated progression, due to the lack
of an untreated control group. For 33 children reviewed 1 and
3 years after stopping atropine, myopia progression eventually
slowed to an annualized rate of 0.06 D per year, presumably
reflecting at least in part, the normal age-related decline in
myopia progression.
In the ATOM studies, concentration- and age-related
rebound in myopia progression was observed in children
followed for a year after termination of atropine treat-
ment.115,117,119 Measured in refractive error terms, this
rebound effect is likely to reflect, at least in part, the recovery
of ciliary muscle tone, which will have been most strongly
inhibited by the highest concentration. However, pharmaco-
dynamic mechanisms are also likely to be at play; specifically,
continuous long-term exposure to pharmacological antagonists
is well known to cause upregulation of receptors, resulting in a
loss of efficacy (tolerance) to the applied drug over time, and
exaggerated symptoms when treatment is terminated.131
Younger children and those previously treated with higher
concentrations of atropine proved most at risk in these ATOM
studies. Specifically, over a 1-year washout period following 2
years of treatment, progression of >0.5 D was observed in 68%
and 59% of children treated with 0.5% and 0.1% atropine
compared with 24% for 0.01% atropine. For 0.01% atropine,
progression of >0.5 D was observed in 62%, 27%, and 8% of
children who were 8 to 10, 10 to 12, and 12 to 14 years old,
respectively, when the treatment was terminated.119 Interest-
ingly, children who recorded almost no myopia progression
(<0.05 D/y) in the year before the termination of treatment
were less likely to show a rebound effect, compared with those
showing residual progression (0.12–0.24 D/y).119 Note also
that at the end of the washout period, eyes previously treated
with the highest, 1% atropine concentration were shorter than
the other groups, despite an increase in the rate of elongation
relative to treatment values.115
3.2.5 Side Effects of Topical Atropine Treatment. The
primary ocular side effects of topical atropine reflect the
inhibitory actions of atropine on the iris sphincter and ciliary
muscles, resulting in mydriasis and reduced accommodation
and symptoms of glare and blur at near. Such side effects may
lead to poor compliance on the part of users, as suggested in
some studies.114 That they can also be effectively addressed
together through the prescription of tinted (photochromatic),
progressive spectacles is reflected in the relatively low loss to
follow-up rate (13.5% at 2 years) in the ATOM1 study, which
applied this strategy.118 As expected, the severity of these side
effects was concentration-dependent; they also may be
ethnicity-dependent. With 0.5% and 0.1% concentrations, pupil
dilatation by 3.5 and 2.3 mm, respectively, and loss of
accommodation by up to 10 to 11 D were documented in
the ATOM studies, with much smaller changes of approxi-
mately 1 mm and 4 D with 0.01% atropine.116,118 Consistent
with these results, only 7% of subjects treated with 0.01%
atropine took up the offer of photochromatic progressive
spectacles, compared with 60% to 70% treated with the higher
0.1% and 0.5% concentrations.116 Fang and colleagues111 noted
similar findings of glare with 0.025% atropine, with 16%
complaining, although none reported near blur. A very low
incidence of side effects was also reported in the study of
Caucasian children by Clark et al.,112 in which only 2 (4%) of
49 children using 0.01% atropine reported intermittent blur
and glare. The trends just described are also consistent with
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results of a meta-analysis by Gong et al.,136 who reported
photophobia rates of 6.5%, 17.5%, and 43.1% for low (0.01%),
moderate (0.01%–0.5%), and high (1%) concentrations. They
also noted less near vision symptoms with the low, compared
with moderate and high concentrations of atropine (2.3%,
11.9%, and 11.6%, respectively; Table 5).
Allergic reactions represent the other, most common ocular
side effect of atropine, with symptoms ranging from mild itch
to follicular reactions and lid erythema, and reported
incidences ranging from 0% to 4%.108,114,118120,136 More
severe forms of allergic keratoconjunctivitis and lid erythema
and rashes also can occur, and on occasion, may be sufficiently
severe as to preclude continued use of atropine.
Concerns over the possibility of adverse effects on IOP,
lens, and retina secondary to pupil dilation appear not to be
justified.102 In one study involving 1% atropine, IOPs
remained within 5.5 mm Hg of baseline values.118 Likewise,
Wu and colleagues137 and Lee and colleagues138 reported no
significant changes in IOP over a range of atropine concen-
trations. To-date there also has not been any report of
lenticular changes linked to chronic topical atropine therapy
applied for 2 to 3 years.117,137 Studies of retinal effects of
chronic topical atropine are limited to MF electroretinogram
(mfERG) and full-field electroretinogram (ffERG) recordings
as part of the ATOM studies. In ATOM1, no significant
differences in mfERG amplitude and implicit times between
treatment and placebo groups for posterior pole responses
were found after 2 years of treatment.139 In the ATOM2 study,
ffERG recordings revealed a reduction in cone function over
time (i.e., after 24 and 32 months), but the changes appeared
tied to AL changes, with no significant atropine concentra-
tion–related differences.140
Systemic adverse effects of topical atropine eye drops are
also possible, with the risk of systemic toxicity being higher in
younger patients, due to their smaller body size. Possible side
effects include dry skin, mouth, and throat, drowsiness,
restlessness, irritability, delirium, tachycardia, and flushing of
the face or neck.141 Nonetheless, in two of the largest clinical
trials of topical atropine, the ATOM1 and ATOM2 stud-
ies,115119 none of the reported adverse events were thought
to be associated with atropine, and there have been no reports
of significant adverse systemic side effects in other studies
using topical atropine for myopia progression (i.e., in children
older than 6 years).140 However, practitioners using atropine
need to be aware of these side effects, as some children may be
hypersensitive to atropine.142
3.3 Pirenzepine
3.3.1 Effects on Myopia Progression. Pirenzepine, an
M1 muscarinic receptor antagonist, has shown promising
effects in reducing myopia progression in children.145147 A
double-masked, placebo-controlled, randomized study in an
Asian population used 2% pirenzepine gel administered twice
daily and found myopic progression was reduced by 44% and
axial elongation by 39% compared with the control group over
12 months.146 A US-based, two year multisite clinical trial
yielded a similar reduction in myopia progression with 2%
pirenzepine compared to the placebo treatment, at 41% (0.58
vs. 0.99 D respectively).147 However, the difference in axial
elongation between the groups (0.28 vs. 0.40 mm) did not
reach statistical significance. At this point in time, pirenzepine
is not currently available as a treatment option and appears not
to be targeted by industry for development.
3.3.2 Side Effects of Pirenzepine. Numerous side effects
were noted with 2% pirenzepine gel administered twice daily
over 12 months in one RCT involving an Asian cohort,146
whereas in contrast, 2-year results from the multisite US-based
clinical trial found the drug to have a clinically acceptable safety
profile.
3.4 7-Methylxanthine
The study of oral 7-MX, an adenosine antagonist, in human
subjects has been limited to Denmark. In relation to myopia
control, it has been the subject of a number of animal studies
(see accompanying IMI – Report on Experimental Models of
Emmetropization and Myopia).30 An initial small (n ¼ 68) 12-
month RCT tested 400 mg of 7-MX once per day in myopic
children aged 8 to 13 years and included a placebo control.123
The study was extended for a further 12 months over which all
subjects were treated with 7-MX, either as a once or twice per
day treatment, before treatment was terminated in all subjects.
Although slowing of axial elongation and slowing of myopia
progression were both recorded in this trial, treatment effects
were relatively small. Efficacy was apparently tied to pretreat-
ment (baseline) rates of eye growth and myopia progression.
Thus, for those classified as having moderate and high axial
growth rates, the differences between 7-MX and placebo
groups were 0.055 mm/y (95% confidence interval [CI]
0.114 toþ0.005 mm/y, P¼ 0.073), and0.031 mm/y (95% CI
0.150 toþ0.087 mm/y, P¼0.593), respectively. The matching
refractive error differences were 0.108 andþ0.070 D/y, with
neither difference reaching statistical significance. Interpreta-
tion of the 2-year data collected from this study is challenging,
as all subjects at this time had been treated for at least 12
months with 7-MX, with the only placebo data being that
contained in the initial 12-month data set. Overall, a reduction
in eye elongation appears to be achievable in children with
moderate baseline axial growth rates, although it may not be
achievable in children with high baseline axial growth rates. As
a currently nonregistered compounded drug in Denmark,
dosage decisions for 7-MX remain the responsibility of the
prescribing doctor.
3.4.1 Side Effects of 7-MX. The treatment appears to be
safe. In the above clinical trial, both participants and their
parents were subject to structured interviews about gastro-
intestinal, cardiopulmonary, and central nervous system–
related side effects. No ocular or systemic side effects were
reported.123
TABLE 5. Summary of Design of Meta-Analyses Covering Trials
Involving Topical Atropine for Myopia Control
Studies and Design Features Key Findings
Huang et al. (2016)143
4 RCT studies
0.51.0% atropine: 0.68 D/y and
0.21 mm/y
0.1% atropine: 0.53 D/y and 0.21
mm/y
0.01% atropine: 0.53D/y and 0.15
mm/y
Li et al. (2014)144
4 RCT and 7 cohort studies
Asian children: 0.54 D/y
White children: 0.35 D/y
Odds ratio: 4.47 (95% CI 0.9121.94)
Gong et al. (2017)136
7 RCT and 9 cohort studies
0.570.62 D/y and 0.27 mm/y
(higher doses)
Pooled effect sizes
RCTs: 2.67 (95% CI 1.463.88)
Cohort studies: 1.30 (95% CI 0.61
1.98)
Higher doses: 3.67 (95% CI 1.85
5.50)
Lower doses: 0.68 (95% CI 0.08
1.27)
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3.5 Timolol
3.5.1. Effects on Myopia Progression. The RCT by
Jensen130 had three treatment arms: SV spectacles (n ¼ 51),
bifocal spectacles (n ¼ 57), and SV spectacles þ timolol (n ¼
51). The timolol arm used 0.25% timolol maleate, twice a day.
Children were followed for 2 years, with additional examina-
tions 1 year after completion of the trial. The results were
generally disappointing, with mean myopia progression over
the 2-year study period in the control and timolol groups being
almost identical (1.14 vs. 1.18 D, respectively), and not
significantly different from each other. This was despite
confirmation that timolol lowered IOP significantly, by
approximately 3 mm Hg, with those with high IOP showing
the largest treatment effect. Also, although there appeared to
be a trend toward increasing noncompliance over time,
progression rates did not appear to reflect compliance.
Curiously, higher progression rates appeared associated with
higher IOP in the control group, with this relationship
reaching statistical significance for the girls, with a similar
but not significant trend for boys.
3.5.2. Side Effects of Timolol. In the above trial, side
effects resulted in timolol treatment being discontinued in six
children. For five of the children, symptoms were ocular in
nature, involving stinging, itching, and foreign body sensations,
these symptoms being possibly related to the formulation
rather than to timolol per se.130 Although reports of changes in
ciliary muscle tone with timolol have been reported,148 this
effect tends to be small in magnitude and unlikely to explain
the disturbance to vision reported for two subjects. More
serious systemic side effects of headaches and difficulty in
breathing were reported in only one subject, although these
are well-known side effects of beta-blockers.148
4. ENVIRONMENTAL INFLUENCES AND THE ROLE OF
TIME OUTDOORS FOR MYOPIA PREVENTION AND
CONTROL OVER PROGRESSION
4.1 Introduction
‘‘A robust child, well fed, enjoying a maximum of outdoor
life, is less likely to get tired eyes and subsequent stretching
of the coats of the eyeball and myopia than is a child that
is cooped up indoors all day, sitting over lessons, and
never joining in vigorous outdoor games.’’
This advice from Harman (1916),149 a century ago, was based
on his observations that myopic children tended to engage in
more indoor, near-viewing tasks than their emmetropic peers,
coupled with the obvious point that, at any moment in time, a
child could be only either indoors or outdoors.
The above example reflects much early interest in environ-
mental influences on ocular development. The first rigorous
scientific evaluation of the relationship between time spent
outdoors and myopia was reported in 1989 by Pa¨rssinen et al.150
In a clinical trial testing whether bifocal spectacles slowed
myopia progression, 237 myopic children were asked to
complete a questionnaire detailing, among other things, the
time they spent engaged in outdoor activities. Self-reported time
outdoors was found to correlate with the child’s myopia
progression over 3 years (r ¼ 0.17, P ¼ 0.004). On further
analysis, the association was found to be largely restricted to
boys.151 The authors surmised that the correlation with time
outdoors might be attributable ‘‘simply to being away from
reading and close work.’’ Perhaps because other myopia
researchers also made the very plausible assumption that near
work and outdoor play were inversely correlated, investigation
of the link between time outdoors and myopia stalled for
another decade, until the publication of a series of influential
studies that stressed the potential importance of time outdoors
or time engaged in sports/outdoor activities as being protective
against myopia.152157 It has been hypothesized that the
increased intensity of visible light outdoors may be one factor
playing a critical role in these protective effects.155 Data from
animal studies indicating that bright light exposure during the
day protects against the development of experimental form-
deprivation myopia (findings are less consistent for lens-induced
myopia)158,159 support this notion, although other factors such
as differences in the patterns of retinal image blur exposure
associated with the outdoor environment also may play
roles.160,161 Achieving light levels indoors comparable with
those typical of the outdoor environment would be challenging,
even with high-efficiency light emitting diode (LED) sources.
4.2 Outdoor Studies
In the past decade, the relationship between time outdoors
and myopia has been extensively studied.162166 Although
several cross-sectional152,155,167170 and cohort stud-
ies154,171175 have addressed the issue of the protective role
of increased outdoor time on myopia prevention, randomized
controlled community-based trials are limited to four stud-
ies.176179 Because the evidence linking time outdoors to the
prevention of incident myopia is stronger than that linking it to
slowing the progression of existing myopia,164 with potential
implications for the ocular health management strategies for
children, these two lines of enquiry are reviewed separately.
The key features of the randomized controlled trials are
summarized in Table 6 and of other relevant studies in Table 7.
4.2.1 Outdoors Studies and Myopia Onset. A recent
randomized controlled trial among Chinese elementary school
children in Guangzhou (GOAL),177 reported a 9.1% reduction
in the myopia incidence rate among children participating in
an outdoor program that included a 40-minute-long, compul-
sory outdoor sports class at the end of each school day
compared with the control group (i.e., 30.4% compared with
39.5% [P < 0.01]). Similar protection was reported in an
earlier, albeit much smaller, intervention study involving
Taiwanese primary school children; the myopia incidence
rates were 8.4% and 17.7% for the intervention and control
groups, respectively (9.2% reduction, P ¼ 0.001).176 A third
large-scale trial of primary school children, also based in China,
reported a reduction in the myopia incidence rate by 4.8% in
the intervention group compared with the control group (3.7%
versus 8.5%).178 Most recently, an intervention trial in Taiwan
involving grade 1 school children exposed to increased
outdoor time during school hours (approximately 40 minutes
per day), coupled with encouragement of greater outdoor time
outside of school hours, reported a modest intervention-related
reduction in the myopia incidence rate (14.5% versus 17.4%, P
¼ 0.054).179 The smaller reduction in myopia incidence in this
study compared with the previous Taiwan-based intervention
study176 may reflect the greater daily outdoor time of the
intervention (80 minutes) in the earlier study, coupled with the
recent introduction of the ‘‘Tien-Tien 120’’ policy designed to
promote 120 minutes of outdoor time per day in Taiwanese
schools, which would have increased the outdoor time of all
participants in the trial.
The association between increased time spent outdoors and
protection against myopia in children and adolescents has
been summarized in a recent meta-analysis,162 which linked
every additional 1 hour of outdoor time per week with a
reduction in the risk of myopia by 2% (odds ratio 0.98; P <
0.001). This pooled estimate equates to an odds ratio of 0.87
for every additional 1 hour of outdoor time per day.162 One
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surprising outcome from epidemiology studies in children has
been the consistent finding that the time children spend
engaged in near work outside of school is not, in fact, related to
the time spent outdoors; instead of the expected inverse
relationship, most investigations have found no correlation
between time engaged in near work and time out-
doors,154,155,167,172,174,180 although there have been exceptions
in which an inverse correlation has been reported.181 Thus,
certain children seem to spend relatively long times, both
outdoors and indoors, engaged in reading or studying, whereas
other children spend little time doing either. However, it must
also be recognized that most such studies have relied on
subjective reporting of time spent in such activities.
4.2.2 Outdoor Studies and Myopia Progression. The
evidence for outdoor time being protective against myopia
progression is mixed.174 In two of the four randomized studies
referred to above, the effect of increased outdoor exposure on
myopia progression was weaker than that on incident myopia.
In the first Taiwanese study, mean progression rates in
intervention versus control groups differed by 0.12 D (P ¼
0.18) in myopic children and by 0.18 D (P ¼ 0.02) in
nonmyopic children, with an overall difference of 0.13 D (P
¼ 0.029; Table 6). Similarly, in the more recent intervention
study in Taiwan, an overall 0.12 D difference in progression
was observed (0.35 vs. 0.47 D, P ¼ 0.002), with significant
effects on progression rates observed in both myopic and
nonmyopic children. In this study, children spending greater
time exposed to bright outdoor light conditions (>1000 lux)
each day at school, as measured by wearable sensors, also
exhibited significantly slower myopia progression (0.14 D, P¼
0.02). Substantial differences in myopia progression rates
between the two China-based studies (e.g., 1.59 vs. 0.27
D; control groups), are also reflected in differences in the
statistical significance of the difference between intervention
and control groups, which was 0.17 D for both groups (1.42
vs. 1.59 D, P ¼ 0.04; 0.10 vs. 0.27 D, P ¼ 0.005).
Seasonal trends in myopia progression have been interpret-
ed as indirect evidence of outdoor effects on myopia
TABLE 6. Outdoor Intervention Studies for Myopia Prevention and Progression
Author (Year),
Study Location,
Study Design Type of Intervention Age at Baseline, Refraction Main Findings
He et al. (2015)177
China
School-based, randomized clinical
trial (GOAL study); N ¼ 1848
Intervention group: One
additional 40-minute class of
outdoor activities on each
school day.
Control group: No additional
class.
3-year RCT
67 y, Cycloplegic auto-
refraction
Myopia incidence rate: Intervention
group: 30.4%; Control group: 39.5%;
Diff: 9.1 (95% CI 14.1 to 4.1); P
< 0.001) after 3 y
Myopia progression rates: Intervention
group: 1.42 D (95% CI 1.58 to
1.27 D); Control group: 1.59 D
(95% CI 1.76 to 1.43 D)
Diff: 0.17 D (95% CI 0.01 to 0.33 D); P
¼ 0.04 after 3 y
Lost to follow-up: 4.7%
Jin et al. (2015)178
China
School-based, prospective,
interventional study; N ¼ 3051
Intervention group: Two
additional 20-minute ROC
programs, in the morning and
afternoon.
Control group: No program.
1-year RCT
614 y, Cycloplegic auto-
refraction
Myopia incidence rate: Intervention
group: 3.7%; Control group: 8.5%; Diff:
4.8% (P ¼ 0.048) after 1 year
Myopia progression rate: Intervention
group: 0.10 6 0.65 D; Control
group: 0.27 6 0.52 D; Diff: 0.17 D
(P ¼ 0.005) after 1 year
Lost to follow-up rate: 10.7%
Wu et al. (2013)176
Taiwan
School-based, interventional trial;
N ¼ 571
Intervention group: Two
additional 40-minute ROC
programs, in the morning and
afternoon.
Control group: No program
1-year RCT
711 y, Cycloplegic auto-
refraction
Myopia incidence rate: Intervention
group: 8.41%; Control group: 17.65%;
Diff: 9.24% (P ¼ 0.001) after 1 year
Myopia progression rate: Intervention
group: 0.25 6 0.68 D; Control
group: 0.38 6 0.69 D; Diff: 0.13 D
(P ¼ 0.029) after 1 y
Wu et al. (2018)179
Taiwan
School-based interventional trial;
N ¼ 693
Intervention group: 40-minute
ROC in morning and
encouragement to undertake 4
additional outdoor leisure
activity programs; in addition to
120 min/d outdoors during
school hours (‘‘Tien-Tien 120’’),
150 min/wk outdoor sports
(‘‘Sport and Health 150’’).
Control group: 120 min/d
outdoors during school hours
(‘‘Tien-Tien 120’’), 150 min/wk
outdoor sports (‘‘Sport and
Health 150’’).
1-year RCT
67 y, Cycloplegic auto-
refraction
Myopia incidence: Intervention group:
14.5%; Control group: 17.4%; Diff:
2.9% (P ¼ 0.054) after 1 year
Myopia progression: Intervention group:
0.35 6 0.58 D; Control group: 0.47
6 0.74 D; Diff: 0.12 D (95% CI 0.05 to
0.19; P ¼ 0.002) after 1 year
GOAL, Guangzhou Outdoor Activity Longitudinal study; ROC, Recess Outside the Classroom; Diff, Difference.
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progression, with faster myopia progression during the darker
winter than the brighter summer months.182,183 For example,
the US-based COMET study reported less myopia progression
in a cohort of ethnically diverse children across the summer
than winter (0.14 6 0.32 vs.0.35 6 0.34 D, respectively; P
< 0.0001).183 Similar differences in myopia progression were
reported among Chinese children (0.31 6 0.25 vs. 0.53 6
0.29 D; P < 0.001), with axial elongation data being consistent
with these refractive error data, that is, eyes elongated less in
summer than in winter (0.17 6 0.10 vs. 0.24 6 0.09 mm; P <
0.001).182
4.3 Vitamin D and Myopia
Inadequate vitamin D has been suggested as a mechanism
linking myopia and insufficient time spent outdoors.184,185
Apart from dietary intake of vitamin D from animal products
and vitamin supplements, it is also synthesized in the skin
when exposed to sunlight and thus ultraviolet (UV) radiation.
Both sources contribute to serum levels of vitamin D. A
number of studies have reported lower levels of serum vitamin
D in myopes compared with non-myopes.185191 Although an
association between serum vitamin D and refractive error
might seem inevitable, given the association between sunlight
exposure outdoors and myopia (i.e., serum levels of vitamin D
might simply represent a surrogate for outdoor exposure),
evidence of a causal relationship comes from the smaller
number of investigations that have reported serum vitamin D
to be significantly associated with myopia (or greater AL) after
adjusting for time outdoors.187,189,192,193 Nonetheless, two
studies that addressed the issue of causation more directly
found minimal support. First, in a longitudinal study of
European children, serum vitamin D did not account for the
association between time outdoors and myopia.188 Second, in a
Mendelian randomization study by the CREAM consortium,
naturally occurring genetic variants known to lower vitamin D
levels were not associated with refractive error, strongly
suggesting a noncausal relationship.194,195
4.4 Indoor Lighting and Myopia
Time spent outdoors is often low due to urbanized lifestyles.
For instance, exposure to air pollution may be a concern to
parents, rain or snow may be off-putting, or activities that
occur outdoors may sometimes be organized to take place in
the evening or at night. Therefore, there is interest in
understanding if high indoor ambient lighting can prevent
myopia development. A study from China found that elevating
light levels in school classrooms from approximately 100 to
500 lux reduced the incidence of myopia in the following year
(4% versus 10%; P ¼ 0.029).196 Although another study
reported an association between fluorescent versus incandes-
cent desk light use and myopia, it did not control for
socioeconomic status.197 To-date there have been no related
studies into the influences, if any, of newer light sources, such
as LEDs. Nonetheless, the French Agency for Food, Environ-
mental and Occupational Health and Safety (ANSES) recom-
mended avoiding the use of LED light sources emitting cold-
white light (light with a strong blue component) in places
frequented by children (e.g., maternity wards, nurseries,
schools, leisure centers), to prevent possible ocular phototox-
icity.198 Human myopia studies in this field are few in number,
TABLE 7. Outdoor Studies for Myopia Prevention and Progression
Author (Year) Study Location,
Study Design
Age at Baseline,
Refraction Main Findings
Prevention
Jones et al. (2007)154 USA (OLSM),
cohort study; N ¼ 514
8–9 y, cycloplegic auto-refraction Time outdoors (h/wk) and incident myopia (SER 
0.75 D): OR ¼ 0.91 (0.87 to 0.95); P < 0.0001
Guggenheim et al. (2012)172 UK,
cohort study (ALSPAC); N ¼ 7747
7 y, noncycloplegic auto-refraction Time outdoors (h/wk) and incident myopia (SER 
1.00 D): HR ¼ 0.76 (95% CI 0.60–0.96); P ¼ 0.02;
Lost to follow-up: 37.6%
French et al. (2013)164 Australia,
(SAVES), cohort study; N ¼ 2103; 56-
y follow-up
6 and 12 y, cycloplegic auto-refraction Time outdoors (h/wk) and incident myopia (SER 
0.50 D): 12-y-olds: OR ¼ 2.84 (95% CI 1.56–5.17)
P < 0.0001; 17-y-olds: OR ¼ 2.15 (95% CI 1.35–
3.42); P ¼ 0.001; Lost to follow-up: 51.6%
Mutti et al. (2002)152 USA (OLSM),
cross-sectional; N ¼ 336
1314 y, cycloplegic auto-refraction Time outdoors (h/d) and myopia (SER  0.75D): OR
¼ 0.92 (95% CI, 0.86 to 0.97); P ¼ 0.005
Rose et al. (2008)155 Australia (SMS),
cross-sectional; N ¼ 2339
6 and 12 y, cycloplegic auto-refraction Time outdoors (h/d) and SER: 6-y-olds: b ¼ 0.05; P ¼
0.009; 12-y-olds: b ¼ 0.07; P < 0.0003
Dirani et al. (2009)167 Singapore
(SCORM), cross-sectional; N ¼ 1249
1120 y, cycloplegic auto-refraction Time outdoors (h/d) and myopia (SER  0.50 D): OR
¼ 0.90 (95% CI 0.84–0.96); P ¼ 0.004
Low et al. (2010)168 Singapore
(STARS), cross-sectional; N ¼ 3009
672 mo, cycloplegic auto-refraction Time outdoors (h/d) and myopia (SER  0.50 D): OR
¼ 0.95 (95% CI 0.85–1.07); P ¼ 0.44
Guo et al. (2013)169 China, cross-
sectional; N ¼ 681
513 y, noncycloplegic auto-refraction Time outdoors (h/d) and myopia (SER  1.00 D): OR
¼ 0.32 (95% CI 0.21–0.48); P < 0.001
Progression
Jones-Jordan et al. (2012)157 USA,
cohort study (CLEERE); N ¼ 835
614 y, cycloplegic auto-refraction Time outdoors (h/wk) and SER change: b ¼ 0.03 (99%
CI 0.03 to 0.08); P > 0.01 for additional 10 h of
outdoor time/wk
Li et al. (2015)174 China, cohort study;
(ACES), N ¼ 2267
1015 y, cycloplegic auto-refraction Time outdoors (h/d) and AL change: b ¼ 0.036 (95%
CI 0.063 to 0.009); P ¼ 0.009; Lost to follow-up:
16.6%
ACES, Anyang Childhood Eye study; ALSPAC, Avon Longitudinal Study of Parents and Children; CLEERE, Collaborative Longitudinal Evaluation of
Ethnicity and Refractive Error study; HR, hazard ratio; OLSM, Orinda Longitudinal Study of Myopia; OR, odds ratio; SAVES, Sydney Adolescent
Vascular and Eye Study; SCORM, Singapore Cohort study of Risk Factors for Myopia; SMS, Sydney Myopia Study; STARS, Strabismus, Amblyopia and
Refractive error Study.
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although a recent large-scale, cross-sectional China-based study
reported higher levels of myopia in young teenagers (1314
years old), using LED compared with incandescent and
fluorescence lamps for homework.199 However, the light levels
in many indoor environments, even rooms with windows, are
also considerably lower than outdoors.199
5. SURGICAL INTERVENTIONS FOR CONTROLLING
MYOPIA PROGRESSION
5.1 Introduction
It is well accepted that most human myopia is axial in nature,
with the greater than normal ALs being the by-product of
reduced collagen synthesis and increased collagen degrada-
tion (see accompanying IMI – Report on Experimental Models
of Emmetropization and Myopia),30 thereby leading to
progressive thinning of the sclera and increasing biomechan-
ical instability. Except in the very young, when emmetropiza-
tion is still active, myopia is largely irreversible. The excessive
ocular elongation that underlies myopia is coupled to
secondary thinning of the retina and choroid,200202 which
is linked to an array of potentially sight-threatening compli-
cations, including retinal detachment, retinoschisis, myopic
maculopathy, and choroid atrophy.203205 High myopes may
also present with limited ocular motility and/or strabismus, as
the extraocular muscles become increasingly stretched and
the space within the orbital space becomes increasingly
crowded.
Among those most at risk of complications in adult life are
children presenting with myopia at a very young age, as they
tend to show faster myopia progression and the window for
myopia progression is also consequently longer.206210 For
those with high myopia, continued ocular elongation during
adulthood unrelated to visual activities, such as scleral
creep,211,212 is not uncommon, further elevating the risk of
retinal and choroidal complications, especially in the case of
posterior staphylomas resulting from localized mechanical
failure of the sclera.
Surgical interventions for stabilizing the sclera and so
controlling further myopia progression have a long history,
with interest revitalized more recently due to climbing myopia
prevalence figures overall and also for high myopia. Procedures
for stabilizing the sclera, by way of preventing or slowing
further ocular elongation aim to reduce or eliminate the above
pathological retinal and choroidal complications. Those
described in the literature fall into three main categories:
scleral reinforcement surgeries, such as posterior scleral
reinforcement (PSR), injection-based scleral strengthening
(SSI), and collagen cross-linking scleral strengthening (CCL),
although the clinical application of these approaches has been
largely limited to PSR, which has been used in both adults and
children with high myopia.
PSR involves surgical implantation under general anesthe-
sia, with a variety of materials having been used, ranging from
fascialata, as first proposed by Shevelev in 1930,213 and also
used by Curtin (human fascia lata),214 as well as lyophilized
dura,215 strips of tendon,216 aorta,217 and donor sclera.218,219
Based on published reports, donor sclera has been and
remains the most popular, although there appears to have
been no head-to-head comparison of available materials to
establish the best material for this reinforcement surgery. A
range of scleral implant shapes also have been used, including
X- and Y-shapes and single strips, with the latter being used in
the technique described by Snyder and Thompson.219,220
Their technique, which uses a single, wide strip of sclera
placed vertically over the posterior pole, under the inferior
oblique but superior to the insertion of superior oblique
muscle, also appears to have been widely adopted. Currently,
PSR for high myopia is mainly performed in Russia, Eastern
Europe, and China, although there are also advocates for
scleral reinforcement for pathologic myopia in the United
States221,222 and Australia.223225
In terms of studies documenting the efficacy of the various
surgical interventions for high myopia, there are 12. All but one
of those documented in Western journals involve either
retrospective case series or case-control studies and all involve
PSR (Table 8), although many lack key details. Not well
represented are studies undertaken in Russia, where PSR and
also SSI appear to be in use.
5.2 Posterior Scleral Reinforcement
Table 8 shows the summary of results from 12 studies using
PSR, published over the period 1961 to 2016.214,218221,227232
The length of intervention and/or monitoring period varies
across these studies, from 1 to 14 years, with subjects ranging
from young children with high myopia to adults with
extremely high myopia.
Most studies report positive outcomes, with PSR halting or
retarding myopia progression and/or AL elongation. An
exception is the 1987 study by Curtin and Whitmore,227
which reported increases in AL of 0.3 mm or more in 90% of
patients undergoing PSR, leading to a decline in popularity of
this surgery in the United States, despite earlier upward
trends in its use over the period 1960 to 1987. Of note, Curtin
and Whitmore214,227 used X-type implants in their PSR, which
has seldom been used in other studies and was not adopted
by Snyder and Thompson219 in their simplified PSR tech-
nique, which uses a single, wide strip of sclera implanted over
the posterior pole. The rationale for the latter choice was to
increase scleral resistance in eyes with progressive myopia
and posterior staphyloma. Over 10 years later, the effective-
ness of this approach appears to be borne out by the 4-year
results of a retrospective study of adult myopes221; eyes
undergoing PSR showed an average axial elongation of 0.1
mm compared with 0.8 mm for fellow, untreated eyes. The
baseline refractive error and AL parameters for these patients
ranged from 9 to 22 D and 28 to 35 mm, respectively.
Several more recent studies in China similarly reported PSR to
be effective in retarding progression in highly myopic
children and adults, although the average treatment effects,
as measured in differences in axial elongation between eyes
undergoing PSR and controls, vary widely, from as little as
0.18 mm230 to 1.05 mm,232 where additional sclera grafts
were applied.
Complications reported in association with PSR surgery
are wide-ranging, and although generally classified as minor,
their occurrence along with the challenging nature of the
surgery likely underlies the still relatively limited use of PSR
by a small number of ophthalmic surgeons. Common
complications include lid edema, chemosis, high IOP, anterior
uveitis, choroid edema, and muscle imbalance. Retinal
hemorrhage and retinal detachment have also been reported,
although causal links to PSR were not conclusively estab-
lished, with high myopia offering an alternative explanation.
There is also a report of cilioretinal artery occlusion 3 years
after PSR in a 12-year-old girl233; however, here also, a causal
relationship seems unlikely.
5.3 Injection-based Scleral Strengthening
There are just two articles reporting on the results of SSIs in
controlling progressive high myopia.234,235 This approach
involves the injection under Tenon’s capsule of chemical
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reagents intended to biomechanically stabilize (‘‘fortify’’) the
extracellular (collagen) matrix of the sclera. One describes a
case series, and the other, a case-control study. No
randomized clinical trials appear to have been undertaken
to-date.
Both studies showed the effectiveness of SSI in retarding of
myopia progression. In the earlier of the two studies by
Golychev and colleagues,235 myopia was reported to have
stabilized in 61% of eyes after approximately 2 years. The latter
study was published in the Russian literature, with only limited
procedural details available234; a polymer gel containing a
mixture of polyvinylpyrrolidone, acrilamidehydrazide, and
ethylacrylate was delivered monocularly by a sub-Tenon’s
capsule injection, with fellow eyes serving as controls. This
study also included a control group. Refractions are reported to
have remained stable in 79.6% of eyes, 1 year after the SSI
intervention, and in 52.9% cases, after 4 to 9 years, contrasting
with figures of 40.3% and 13.3% for fellow eyes and 26% and
11.1% for the control group.
5.4 Collagen Cross-linking for Scleral
Strengthening
CCL is increasingly used worldwide for the management of
biomechanically unstable corneas, be they of disease origin,
such as keratoconus, or a complication of refractive surgery.
However, although there is significant interest in the viability of
this approach for stabilizing the sclera in pathological myopia,
testing to-date has been limited to experimental animals.
6. GAPS IN KNOWLEDGE AND FUTURE DIRECTIONS
6.1 Optical Interventions for Myopia Management
Although the results of trials provide convincing evidence for
the efficacy of a number of optical interventions for myopia
control, there remain many unanswered questions related to
underlying mechanisms. These include but are not limited to
the relative contributions of the central and peripheral retinal
TABLE 8. Summary of Key Design Features and Results of Studies Involving PSR Surgery
Study and Country
Origin
Implant Shape
and Material Study Design Baseline (SER and/or AL)
Outcome Measures; Treatment vs.
Control (SER Change per y and/or
AL change per y)
Curtin et al.
(1961)214 (USA)
X-shape; fascialata Retrospective (1.8-y FU, n
¼ 7; fellow eye control),
children
Mean: 13.29 D (range:
11 to 19 D)
0.79 vs. 0.81 D/y
Miller et al.
(1964)218 (USA)
Single wide strip
human sclera%
Retrospective (n ¼ 63; 27
children, 36 adults); no
controls
Range: 9 to 44 D 0.83 D/y overall; 0.55 D/y, children;
1.03 D/y, adults; No increase/
decrease up to 3 D in 26% adults,
22% children
Snyder et al.
(1972)219 (USA)
Single wide strip
human sclera
Retrospective (0.5 mo, 3.5
y FU; 7 children, 3
adults); no controls
17.1 D 0.61 D/y overall; 0.02 D/y, children;
2.00 D/y, adults
Thompson et al.
(1978)220 (USA)
Single wide strip
human sclera
Retrospective (1 mo-7 y
FU; n ¼ 52; 14 children,
37 adults); no controls
Mean: 13.45 D (range:
5.75 to 25 D)
0.48 D/y overall; 0.20 D/y, children;
1.03 D/y, adults
Thompson et al.
(1985)226 (USA)
Single wide strip
human sclera
Retrospective (114 y FU;
n ¼ 191); no controls
Not reported 77 eyes improved 2 Snellen lines or
more; 85 eyes stabilized within 1
Snellen line; 13 eyes lost 2 Snellen
lines or more
Curtin et al.
(1987)227 (USA)
X-shape; autologous
fascialata
Retrospective (5 y FU; n ¼
23; fellow eyes control)
Means: 15.48 D; 28.22
mm
0.19 vs. 0.06 D/y; 0.14 vs. 0.12
mm/y
Ward et al.
(2009)221 (USA)
Single wide strip
human sclera
Retrospective; adults (4 y
FU; n ¼ 59; fellow eye
control)
Ranges: 9 to 22 D; 27.8
34.6 mm
0.07 vs. 0.21 mm/y
Chen et al.
(2013)228 (China)
Single wide strip
human sclera
Retrospective; children (n
¼ 64, 5 y average FU; 17
extra eyes as controls,
4.5 y average FU)
Means: 10.31 D; 26.55
mm
1.5 vs. 3.02 D; 1.27 vs. 2.05 mm
Zhu et al. (2014)229
(China)
Single wide strip
human sclera þ
PIOL implantation
Retrospective; adolescents
(3 y FU; n ¼ 11 and 11
controls)
Means: 17.57 D; 30.09
mm
4.96 vs. 1.22 D/y; 0.08 vs. 0.37
mm/y
Xue et al. (2014)230
(China)
Single wide strip
human sclera
Retrospective; children (2.5
y average FU; n ¼ 30,
fellow eye control);
Means: 9.72 D; 26.2 mm 1.12 vs. 1.82 D; 0.75 vs. 0.94 mm
(over average 2.5 y FU)
Shen et al. (2015)231
(China)
Single wide strip
human sclera
Prospective; children (3 y
FU; n ¼ 16 and 16
controls)
Means: 11.82 D; 26.78
mm
0.44 vs. 0.23 D/y; 0.20 vs. 0.44
mm/y
Li et al. (2016)232
(China)
Single wide strip
human sclera þ
additional scleral
graft
Retrospective; adults (5 y
FU; n ¼ 52 and 52
controls)
Means: 16.12 D; 29.49
mm
0.14 vs. 0.64 D/y; 0.06 vs. 0.27
mm/y
FU, follow-up; PIOL, phakic intraocular lens.
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regions to eye growth regulation, the influences if any, of
altered aberrations, including imposed positive spherical
aberration, as inherent in some of the contact lens treatments,
and of add power. Studies using dual-power lenses based on
the Fresnel principle to investigate the effects on eye growth of
imposed myopic defocus in experimental animals236238
suggest that the retinal location may be less important than
the total retinal area involved. This observation raises the
question of whether near center soft contact lenses may also
be effective in controlling myopia. Whether the OK lens can be
further optimized to improve treatment outcomes remains an
open question. Of note among new OK lens designs being
explored is one that purports to provide simultaneously, both a
vision correction area and a myopic defocus area (positive
power within the pupil region) (US 9753309 B2). The effect of
occasionally interrupting MF treatments, for example, to obtain
more acceptable vision for specific tasks, on treatment efficacy,
is also not known. On the other hand, for OK wearers with
rapidly recovering corneas, it might be possible to combine
OK with daily wear MF contact lenses, by way of extending in
time, an optical treatment effect. At least some of these
questions may be suitably addressed in further animal studies,
as a stepping stone in designing follow-up clinical trials.
6.2 Pharmacological Control of Myopia
Although there have been many studies assessing atropine as
an intervention for myopia control, and many more are
currently under way, there remain a number of important
unanswered questions. For example, the exact ocular site of
action of atropine’s inhibitory effect on myopia progression
remains unresolved, with the sclera, choroid, and retina among
possibilities; underlying cellular and pharmacological mecha-
nisms also remain unresolved.239,240 Until consensus is reached
on the ocular tissue to be targeted, advances in drug delivery
cannot been fully exploited to optimize formulations. Addi-
tional studies are also needed to establish optimal atropine
dosing and treatment regimens, including how long treatment
should be continued, when/how it should be stopped, and the
possibility of ‘‘prescribing’’ short drug holidays to prevent
tolerance with higher concentrations.131,241 The safety of
extended chronic atropine treatment in very young (<6 years),
and its efficacy in older children (>12 years), and in both those
who are not yet myopic, as a preventative strategy, and in those
with very high myopia (>6 D), also can benefit from further
research. The benefits in later adult life, of early intervention
(e.g., in terms of protection against myopia-related pathological
complications), as well as the potential for very long-term side
effects are as yet unknown and warrant investigation. The
predicted increasing need for myopia control treatments
would also seem sufficient argument for further investigations
into the efficacy of topical pirenzepine, which has dropped off
the radar, despite promising early results.143,146,147
There is room for further research into 7-MX and related
compounds. It is possible that efficacy could be improved with
improved formulations (e.g., sustained-release formulations
instead of a standard tablet formulation), given that even twice
per day dosing may not be sufficient to maintain an effective
serum concentration level of 7-MX, which has a relatively short
half-life.123 The effect of 7-MX on myopia progression is
believed to rely on inhibiting adenosine receptors in the
posterior part of the eye. However, although experimental
studies involving rabbits and guinea pigs point to beneficial
effects on the sclera, including thickening and increases in
collagen fiber size,242 adenosine receptors have also been
localized in the retina, the retinal pigment epithelium, and the
choroid, with significant choroidal thickening along with
increased hyperopia being reported in a recent study involving
young monkeys.124 Thus, further research to understand
underlying mechanisms is warranted. Investigations into the
viability of topical ophthalmic formulations of 7-MX or related
drugs would also allay concerns over systemic side effects,
with its longer-term use in developing children. That 7-MX
might be combined with other intervention methods, optical
or pharmaceutical, to increase treatment efficacy, is also yet to
be explored.
Although disappointing results of the timolol RCT by
Jensen130 generally dampened enthusiasm for further testing
of IOP-lowering drugs as an approach to myopia control, it is
possible that the choice of timolol was also poor. For example,
it is known clinically that timolol has little effect on night-time
IOP,243 yet some animal studies have shown ‘‘myopic growth’’
to occur mostly at night.244 The very positive results from a
related clinical study involving carteolol, a partial beta agonist,
undertaken in Argentina245 and on-going experimental studies
involving other ocular hypotensive drugs, including latano-
prost, a prostaglandin analogue,246 and brimonidine, an alpha2
adrenergic agonist,247 argue for further exploration of this
treatment option, given the potential secondary prophylactic
benefit of such therapies against primary angle glaucoma for
which myopes are at increased risk (see accompanying IMI –
Defining and Classifying Myopia Report).134
6.3 Environmental Influences and the Role of Time
Outdoors
In relation to environmental influences on refractive errors
and, importantly, the potential for outdoor exposure to protect
against myopia onset and perhaps also slow myopia progres-
sion, there remain as many unresolved questions as there are
answers. What is the mechanism of action underlying the
protective effect of outdoors and what are the key temporal
factors? For example, does the reduced risk of incident myopia
reach a plateau beyond a certain length of time outdoors and is
2 hours per day outdoors presented in one block more or as
effective as two 1-hour exposures per day. Does the time of day
matter and perhaps related, is there an optimum light intensity
and spectral composition? Does the age of the child matter and
does it matter what the child is doing when outdoors? For
example, does it matter if the child is using a smartphone
outdoors versus gazing at distant objects outdoors? Are the
parameters different regarding protection against incident
myopia versus myopia progression?
The role of differences in behavior as a determinant of
susceptibility to myopia is just beginning to be addressed, with
the adoption of wearable light sensors and accelerometers,
which allow more accurate characterization of light exposure,
including time spent outdoors, as well as physical activity,
compared with traditional questionnaire-based studies. Tools
already deployed in research include the HOBO and Acti-
watch,248,249 with preliminary testing of a smartwatch (Fit-
Sight) linked with a smartphone app, aimed at increasing
outdoor exposure also covered in a recent publication.250
Interest in measuring working distances stems, at least in part,
from early reports linking habitually short working distances
and pronounced head tilts with a greater risk of myopia,251 as
well as prolonged exposure to activities with near working
distances with myopia.252 With increasing reliance of electron-
ic devices/screens in education as well as in daily life, it is now
plausible to integrate into electronic devices/screens, applica-
tions that promote better reading posture. Previews of a
customized spectacle-frame mounted distance sensor, the
Cloudclip, and an eye tracker with attached distance sensor
were presented at the 16th International Myopia Conference
(Birmingham, UK, 2017), and it seems only a matter of time
before such devices will be able to send reminders to wearers
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to keep an appropriate distance from their reading material. In
addition, smart garments, such as designed for spinal and
posture alignment therapy, may also be used for providing
feedback to children exhibiting chronically poor reading
posture.253 As smart technologies become integrated into
myopia control treatments, as opposed to their use as research
monitoring devices, evaluation of their effectiveness in slowing
myopia progression will be required. Clinical trial design and
tools for quantifying outdoor activity are covered in the
accompanying IMI – Clinical Myopia Control Trials and
Instrumentation Report.133
6.4 Surgical Interventions for Controlling Myopia
Progression
There is accumulating evidence that PSR is somewhat effective
in stabilizing high myopia, despite the limitations of the studies
reporting on the efficacy of this procedure. Clinical evaluation
of the other two surgical options, SSI and CCL, is either limited
(SSI) or nonexistent CCL). Nonetheless, there are significant
clinical advances being made in CCL for corneal applica-
tions254 and strong interest in its application for human myopia
control, with related on-going investigations using animal
models for myopia.255257 For the PSR, the difficulty of surgery
makes it unpopular with ophthalmic surgeons. Apart from the
commonly reported complications, the possibilities of optic
nerve contusion or compression, and retrobulbar hemorrhage
due to vortex vein or ciliary artery injury, are other concerns.
There is also the need for general anesthesia. Thus a simple and
safe surgical technique that can be performed under local
anesthesia and that would also allow precise localization of the
scleral implant over the posterior pole (macular region) would
be more appropriate. Perhaps more urgent is the need for a
synthetic scleral implant that is both biocompatible and
biostable; such materials would reduce the risk of infection
and rejection; they would also address the longer-term concern
of a future shortage of healthy donor sclera, given the
continuing rise in myopia prevalence figures.
In the case of SSI, more extensive studies of the material
already in use in Russia would help to allay concerns over
potential ocular toxic effects on nearby tissues, including the
choroid and retina. Testing of related materials in the chick as
an experimental myopia model did not show slowing of ocular
elongation in either of two studies,258,259 although significant
thickening of the outer fibrous layer of the chick sclera with a
thermoresponsive material (poly[N-isopropylacrylamide-co-
acrylic acid]) represents a positive finding. Another more
recent study involving a potentially more biocompatible,
hyaluronic acid–based polymer and a guinea pig myopia model
did show slowed elongation, but curiously, so did sham-
injected eyes.260 These promising results, along with the fact
that the procedure used in this study may be modified to avoid
the need for general anesthesia, argues for further investiga-
tions into this approach, starting with exploration of alterna-
tive materials and more extensive investigations into both
potential benefits and potential adverse ocular effects.
CCL techniques currently under investigation can be
classified into two categories based on whether or not UV
radiation is required as an initiator of the reaction. For highly
myopic eyes with thinned scleras, possible damage of retina
during UV irradiation makes protocols that do not rely on UV
radiation more attractive. There is also another technical issue
to be addressed, of how to adequately expose the posterior
sclera of highly myopic eyes with the light activator, as
required in all current protocols. Among other issues to be
addressed is the enduring nature of scleral cross-linking;
specifically, how long lived are any treatment-induced increas-
es in scleral stiffness, and are changes sufficient to slow ocular
elongation.
6.5 Combination Therapies for Myopia Control
Considering that no one intervention strategy of those
currently available (optical, pharmacological, or behavioral)
has proven effective in totally inhibiting myopia progression, in
either refractive error or AL terms (see recent meta-analy-
sis),143 it would seem timely to begin exploring combination
therapies as an approach for improving treatment efficacy.
Although there remain many unanswered questions in
relation to the mechanism of action of topical atropine, used as
a myopia control treatment, the possibility that sites other than
the retina may be involved argues for its testing in combination
with optical approaches. To-date, there is only one relevant
clinical trial listed (clinicaltrials.gov identifier: NCT02955927)
(Kinoshita N, et al. IOVS 2017;58:ARVO E-Abstract 2386).
Nonetheless, the 1-year results for a 2-year trial, in which the
efficacy of 0.01% atropine combined with OK is being
compared with OK alone in 8- to 12-year-old children, are
very promising. Specifically, the combination yielded an
improved outcome (reduced axial elongation), by more than
50% (axial elongation: 0.09 6 0.12 vs. 0.19 6 0.15 mm). Also
of potential relevance are investigations into the atropine
release profile of soft contact lens materials261; should atropine
be considered for combination therapy with MF soft contact
lenses, then it would be reasonable in the interest of
compliance to use the lenses as a drug-delivery device. The
effectiveness of such drug-delivering lenses on slowing myopia
progression would need to be substantiated with longitudinal
studies in children. Combining contact lens–based treatments
with other drug treatments, such as oral 7-MX or pirenzepine,
both of which would avoid any concerns over adverse drug–
contact lens interactions, are among other potential avenues to
explore.
7. OVERALL CONCLUSION
The current myopia epidemic shows no sign of abating. This
article covers a variety of interventions, aimed at preventing
the development of myopia and/or slowing its progression. No
one strategy appears to reliably achieve either outcome in all
individuals. On-going research may lead to a better under-
standing of underlying mechanisms that can be applied to
identify those most likely to respond to specific interventions
and to also inform combination therapies, which are currently
used on an ad hoc basis. This field also could benefit from
longer-term studies of the various interventions covered in this
article, to better understand the persistence of treatment
effects over time, as well as from exploration of more novel
approaches to myopia control.
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